



Commercial/Healthcare Exchange PA Criteria
Effective: January 1, 2021

Prior Authorization: Dronabinol

Products Affected: Dronabinol 2.5mg, 5mg, 10mg capsule

Medication Description: Dronabinol is an orally active cannabinoid which, like other cannabinoids has complex effects on the central nervous system, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues which may play a role in mediating the effects of dronabinol.

Covered Uses:

1. Treatment of anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS).
2. Treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Previous therapies tried/failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

Anorexia associated with weight loss in patients with AIDS

1. Patient has a diagnosis of Acquired Immune Deficiency Syndrome (AIDS) and has anorexia associated with weight loss; **AND**
2. Patient has a documented intolerance to, contraindication, or treatment failure with megestrol oral suspension

Nausea and vomiting associated with cancer chemotherapy

1. Patient has nausea and vomiting associated with cancer chemotherapy; **AND**
2. Patient has a documented intolerance to, contraindication, or treatment failure with a 5-HT₃ antagonist (e.g. ondansetron or granisetron)

References:

1. Marinol (dronabinol) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.

Policy Revision history

Last Rev. January 2021

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	1/1/2021

